Source ladders
The protocol's compound choices and dosing windows draw on three overlapping bodies of evidence: classical Chinese herbology, modern pharmacology and clinical trials, and the recent metabolic-syndrome / NAFLD / GLP-1 literature.
The site does not currently inline citations into each page. Annotated source ladders for each window and each tier-1 ingredient are in preparation.
Suggested reading
- Bensky, Clavey, Stöger — Chinese Herbal Medicine: Materia Medica (3rd edition).
- Maciocia — The Foundations of Chinese Medicine.
- Yan-Tang & Zhu — Practical Diagnosis in Traditional Chinese Medicine.
- Yin et al., 2008 — Berberine, a clinically effective hypolipidemic agent. Metabolism.
- Ostojic, 2006 — Yohimbine: the effects on body composition and exercise performance in soccer players. Research in Sports Medicine.
- Dolinsky et al., 2010 — AMPK as a target for metabolic disease and the action of berberine and metformin. Curr Opin Pharmacol.
- Hofmann & Hagey, 2008 — Bile acids: chemistry, pathochemistry, biology, pathobiology.
Index sources
The TCM herb identifications follow the standard Chinese pharmacopeia binomial nomenclature. Where modern pharmacological data is referenced, it is drawn from peer-reviewed clinical and pre-clinical literature published between approximately 2000 and 2024.